BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25052595)

  • 1. [Clinical investigation of reduced-dose voriconazole on primary prevention in invasive fungal disease after allogeneic hematopoietic stem cell transplantation].
    Qiu Z; Ren H; Cen X; Ou J; Xu W; Wang M; Wang L; Dong Y; Li Y; Liu W; Sun Y; Liang Z; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):577-80. PubMed ID: 25052595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
    Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
    Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and Safety of Posaconazoleon for Primary Antifungal Prophylaxis against Invasive Fungal Disease in Patients with Stem Cell Transplantation].
    Wu YM; Cao YB; Li XH; Xu LX; Yan B; Li SW; Wang HT; Gao YH; Zhang TT; Zhang YQ; Wang L; Wu XX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):885-889. PubMed ID: 28641654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation.
    Sun Y; Xu L; Liu D; Zhang X; Han W; Wang Y; Chen H; Chen Y; Wang F; Wang J; Ji Y; Tang F; Liu K; Huang XJ
    Clin Microbiol Infect; 2013 Nov; 19(11):1029-34. PubMed ID: 23565830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience.
    Omer AK; Ziakas PD; Anagnostou T; Coughlin E; Kourkoumpetis T; McAfee SL; Dey BR; Attar E; Chen YB; Spitzer TR; Mylonakis E; Ballen KK
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1190-6. PubMed ID: 23747459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.
    Takagi S; Araoka H; Uchida N; Uchida Y; Kaji D; Ota H; Nishida A; Ishiwata K; Tsuji M; Yamamoto H; Ito T; Matsuno N; Yamamoto G; Asano-Mori Y; Hayashi M; Izutsu K; Masuoka K; Wake A; Makino S; Yoneyama A; Taniguchi S
    Int J Hematol; 2014; 99(5):652-8. PubMed ID: 24664791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
    Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
    Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.
    Liu M; Li Y; Zhang Y; Zhao X; Zhai B; Zhang Q; Wang L; Zhao Y; Li H; Wang Q; Gao C; Huang W; Yu L
    PLoS One; 2014; 9(12):e115461. PubMed ID: 25531544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis.
    Liu Q; Lin R; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Fan Z; Zhou H; Jiang Q; Zhang F; Zhai X; Xu D; Wei Y; Song J; Li Y; Feng R
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1198-203. PubMed ID: 24769013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in incidence of invasive fungal infection in patients receiving allogeneic stem cell transplantation using combined diagnostic-driven approach and itraconazole oral solution.
    Tzadok R; Shapira MY; Moses AE; Or R; Block C; Strahilevitz J
    Mycoses; 2015 Dec; 58(12):694-8. PubMed ID: 26429354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).
    Girmenia C; Raiola AM; Piciocchi A; Algarotti A; Stanzani M; Cudillo L; Pecoraro C; Guidi S; Iori AP; Montante B; Chiusolo P; Lanino E; Carella AM; Zucchetti E; Bruno B; Irrera G; Patriarca F; Baronciani D; Musso M; Prete A; Risitano AM; Russo D; Mordini N; Pastore D; Vacca A; Onida F; Falcioni S; Pisapia G; Milone G; Vallisa D; Olivieri A; Bonini A; Castagnola E; Sica S; Majolino I; Bosi A; Busca A; Arcese W; Bandini G; Bacigalupo A; Rambaldi A; Locasciulli A
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):872-80. PubMed ID: 24631738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease.
    Yáñez L; Insunza A; Ibarrondo P; de Miguel C; Bermúdez A; Colorado M; López-Duarte M; Richard C; Conde E
    Transpl Infect Dis; 2015 Oct; 17(5):761-7. PubMed ID: 26250790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
    Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
    Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
    Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
    Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients.
    Wojenski DJ; Bartoo GT; Merten JA; Dierkhising RA; Barajas MR; El-Azhary RA; Wilson JW; Plevak MF; Hogan WJ; Litzow MR; Patnaik MM; Wolf RC; Hashmi SK
    Transpl Infect Dis; 2015 Apr; 17(2):250-8. PubMed ID: 25661996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.